Castle Biosciences Inc has a consensus price target of $34.27, established from looking at the 31 latest analyst ratings. The last 3 analyst ratings were released from Keybanc, Scotiabank, and Guggenheim on March 1, 2024, March 1, 2024, and December 14, 2023. With an average price target of $30 between Keybanc, Scotiabank, and Guggenheim, there's an implied 35.44% upside for Castle Biosciences Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/01/2024 | CSTL | Buy Now | Castle Biosciences | $22.15 | 26.41% | Keybanc | Paul Knight | $25 → $28 | Maintains | Overweight | Get Alert |
03/01/2024 | CSTL | Buy Now | Castle Biosciences | $22.15 | 67.04% | Scotiabank | Sung Ji Nam | $33 → $37 | Maintains | Sector Outperform | Get Alert |
12/14/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 12.87% | Guggenheim | Subbu Nambi | → $25 | Initiates | → Buy | Get Alert |
08/04/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 12.87% | Keybanc | Paul Knight | $37 → $25 | Maintains | Overweight | Get Alert |
07/07/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 44.47% | Lake Street | Thomas Flaten | → $32 | Reiterates | Buy → Buy | Get Alert |
07/06/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 67.04% | Stephens & Co. | Mason Carrico | → $37 | Reiterates | Overweight → Overweight | Get Alert |
06/15/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 35.44% | BTIG | Mark Massaro | $38 → $30 | Maintains | Buy | Get Alert |
06/07/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 48.98% | Scotiabank | Sung Ji Nam | $54 → $33 | Maintains | Sector Outperform | Get Alert |
06/06/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 80.59% | Canaccord Genuity | Kyle Mikson | $60 → $40 | Maintains | Buy | Get Alert |
06/05/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 58.01% | SVB Securities | Puneet Souda | $50 → $35 | Maintains | Outperform | Get Alert |
06/05/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 44.47% | Lake Street | Thomas Flaten | $41 → $32 | Maintains | Buy | Get Alert |
06/05/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 12.87% | Baird | Catherine Ramsey | $35 → $25 | Maintains | Outperform | Get Alert |
05/08/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 85.1% | Stephens & Co. | Mason Carrico | → $41 | Reiterates | → Overweight | Get Alert |
05/05/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 67.04% | Keybanc | Paul Knight | $40 → $37 | Maintains | Overweight | Get Alert |
05/04/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 85.1% | Stephens & Co. | Mason Carrico | → $41 | Reiterates | → Overweight | Get Alert |
05/04/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 58.01% | Baird | Catherine Ramsey | $38 → $35 | Maintains | Outperform | Get Alert |
03/02/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 85.1% | Stephens & Co. | Mason Carrico | → $41 | Reiterates | → Overweight | Get Alert |
03/01/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 71.56% | Baird | Catherine Schulte | $42 → $38 | Maintains | Outperform | Get Alert |
01/05/2023 | CSTL | Buy Now | Castle Biosciences | $22.15 | 143.79% | Scotiabank | Sung Ji Nam | → $54 | Initiates | → Sector Outperform | Get Alert |
The latest price target for Castle Biosciences (NASDAQ: CSTL) was reported by Keybanc on March 1, 2024. The analyst firm set a price target for $28.00 expecting CSTL to rise to within 12 months (a possible 26.41% upside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for Castle Biosciences (NASDAQ: CSTL) was provided by Keybanc, and Castle Biosciences maintained their overweight rating.
There is no last upgrade for Castle Biosciences.
There is no last downgrade for Castle Biosciences.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Castle Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Castle Biosciences was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.
While ratings are subjective and will change, the latest Castle Biosciences (CSTL) rating was a maintained with a price target of $25.00 to $28.00. The current price Castle Biosciences (CSTL) is trading at is $22.15, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.